Results 111 to 120 of about 238,609 (287)

A valent-based metric framework for analyzing intuitionistic fuzzy graphs in uncertain environments

open access: yesAin Shams Engineering Journal
This paper introduces a new notion of distance in intuitionistic fuzzy graphs, termed the Valent distance, which incorporates the degrees (valences) of both vertices and edges.
J. Komathi, D. Meiyappan, K. Anitha
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Computation of mixed resolvability for a circular ladder and its unbounded nature.

open access: yesPLoS ONE
Let Γ = Γ(V ,E) be a simple, planar, connected, and undirected graph. The article primarily concentrates on a category of planar graphs, detailing the explicit identification of each member within this graph family. Within the domain of graph theory, the
Sunny Kumar Sharma   +4 more
doaj   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

open access: yesMolecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

CEACAM1 participation in breast cancer progression

open access: yesMolecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin   +3 more
wiley   +1 more source

ON THE METRIC DIMENSION OF CARTESIAN PRODUCT OF THREE PATHS [PDF]

open access: yes, 2013
A set of vertices S resolves a graph G if every vertex is uniquely determined by its vector of distances to the vertices in S. The metric dimension of a graph G is the minimum cardinality of a resolving set.
Nurdin
core  

The Metric Dimension of Theta Graph [PDF]

open access: yes
Let $ G = (V, E) $ be a connected graph with vertex set $ V(G) $ and edge set $ E(G) $. For any two vertices $ u $ and $ v $ in $ G $, the shortest path distance between $ u $ and $v$ is denoted by $d(u, v)$.
Deddy Rahmadi, Wakhid Fitri Albar
core   +2 more sources

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy